U.S. FTC Hits Delay In Approving Aussie CSL’s Buy Of Talecris
This article was originally published in PharmAsia News
A delay by a U.S. agency is expected to add several months to Australia-based CSL's $3.1 billion acquisition of Talecris Biotherapeutics Holdings. The U.S. Federal Trade Commission has asked for more information about the merger of CSL, the second-largest supplier of blood-plasma products, and U.S.-based Talecris, maker of key treatments for autoimmune diseases. The FTC is supposed to respond within 30 days to merger plans, but a CSL spokeswoman said the review process is now expected to take longer, but before August and the anniversary of the acquisition proposal. The deal hinges on agency approval within 12 months of the offer, and if not met, requires a $75 million fee to the venture company owners of Talecris. (Click here for more
You may also be interested in...
Gilead says remdesivir improved mortality and clinical recovery in COVID-19 patients, but the findings come from a retrospective analysis, not a traditional clinical trial.
Agency resuming domestic inspections with the help of a pandemic rating system to identify localities where inspections will be safest for investigators and plant workers. Another safety factor: all inspections will be pre-announced.
Poseida, Nkarta and Inventiva raised $224m, $252m and $107.7m, respectively. Also, Forbion raised €185m ($208m) of a new €250m fund and Blackstone closed the last $1.2bn of its $4.6bn fund for public and private company deals, and Ascendis led recent follow-ons with a $569.2m offering.